| Use of i.v. immune globulin and occurrence of associated acute renal failure and thrombosis. | |
| | |
MedLine Citation:
|
PMID: 15790799 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The use trends of i.v. immune globulin (IGIV) and the frequency of acute renal failure (ARF) and thrombosis at one institution were studied. METHODS: A retrospective chart review on the indications and dosages of IGIV was conducted with inpatients and outpatients at a Veterans Affairs medical center between May 1, 1998, and June 30, 2003. Patients under 18 years of age were excluded from the study. Patient data were obtained through the center's computerized patient record system and included patient demographics, comorbidities, frequency of ARF, concomitant therapies, and IGIV therapy courses. ARF was defined as an increase in serum creatinine of >/=0.5 mg/dL within 10 days from the initiation of IGIV therapy. RESULTS: Forty-six patients were identified as receiving at least one cycle of IGIV therapy between May 1, 1998, and June 30, 2003. The three main indications for IGIV therapy were hypogammaglobulinemia, idiopathic thrombocytopenic purpura (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). No new cases of thrombosis were found. Six patients (13%) developed ARF after IGIV administration, but none required dialysis. A greater percentage of patients with ARF were 65 years or older, had chronic renal insufficiency or diabetes mellitus, and used nephrotoxic agents, compared with patients who did not develop ARF. No association was observed between ARF and underlying primary disease. CONCLUSION: A retrospective review of 46 courses of IGIV therapy showed that the therapy was most often used for hematologic, neurologic, and immunologic indications, and the most common diagnoses for which it was used were hypogammaglobulinemia, ITP, and CIDP. ARF developed in 13% of patients, but no case of thrombosis was reported. |
| | |
Authors:
|
Sachin Shah; Marne Vervan |
Related Documents
:
|
11136169 - Poor long-term survival after coronary angiography in patients with renal insufficiency. 9892379 - Effectiveness of nutrition interventions in the pre-esrd and the esrd population. 3574569 - Spectral analysis of fluctuations in heart rate: an objective evaluation of autonomic n... 8191619 - Beta 2-microglobulin amyloidosis: illustrative cases. 10352219 - 1997 peritoneal dialysis-core indicators study: dialysis adequacy and nutritional indic... 7802519 - Dialysis discontinuation. a 'good' death? 19903669 - A new approach to confirming or excluding ventricular pre-excitation on a 12-lead ecg. 18216399 - Steady-state pharmacokinetics of nevirapine in hiv-1 infected adults in india. 10599659 - Elevated vitreous interleukin-10 level is not diagnostic of intraocular-central nervous... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 62 ISSN: 1079-2082 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2005 Apr |
Date Detail:
|
Created Date: 2005-03-25 Completed Date: 2005-07-14 Revised Date: 2006-10-13 |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 720-5 Citation Subset: IM |
Affiliation:
|
School of Pharmacy, Texas Tech University, Dallas/Fort Worth, Dallas, TX 75216, USA. sachin.shah@ttuhsc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Aged Aged, 80 and over Hospitals, Veterans Humans Immunoglobulins, Intravenous / adverse effects*, therapeutic use Kidney Failure, Acute / chemically induced* Middle Aged Retrospective Studies Thrombosis / chemically induced* |
| Chemical | |
Reg. No./Substance:
|
0/Immunoglobulins, Intravenous |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Causes of hyperglycemia and hypoglycemia in adult inpatients.
Next Document: Patient-assistance programs: assessment of and use by safety-net clinics.